Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6787161 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(5 years ago) | |
US6432452 | LEO LABS | Anti-cancer compounds |
Aug, 2018
(5 years ago) | |
US6844013 | LEO LABS | Methods of stimulating the immune system |
Dec, 2018
(5 years ago) | |
US7410656 | LEO LABS | Anti-cancer compounds |
Oct, 2020
(3 years ago) | |
US9861603 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8372828 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US9820959 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US9833429 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8377919 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US9833428 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8536163 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8372827 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8716271 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8735375 | LEO LABS | Therapeutic compositions |
Dec, 2026
(2 years from now) | |
US8278292 | LEO LABS | Therapeutic compositions |
Jul, 2027
(3 years from now) | |
US9789078 | LEO LABS | Method of topically treating actinic keratosis with ingenol mebutate cycle therapy |
May, 2033
(9 years from now) |
Picato is owned by Leo Labs.
Picato contains Ingenol Mebutate.
Picato has a total of 16 drug patents out of which 4 drug patents have expired.
Expired drug patents of Picato are:
Picato was authorised for market use on 23 January, 2012.
Picato is available in gel;topical dosage forms.
Picato can be used as treatment of actinic keratosis, to inhibit the proliferative activity of neoplastic cells, topical treatment of actinic keratosis of the face or scalp using more than one treatment course of ingenol mebutate, to stimulate the immune system to induce t cell proliferation, use of ingenol mebutate to treat actinic keratosis.
Drug patent challenges can be filed against Picato from 24 January, 2016.
The generics of Picato are possible to be released after 15 May, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-169) | Nov 19, 2018 |
New Chemical Entity Exclusivity(NCE) | Jan 23, 2017 |
Drugs and Companies using INGENOL MEBUTATE ingredient
NCE-1 date: 24 January, 2016
Market Authorisation Date: 23 January, 2012
Treatment: Treatment of actinic keratosis; To stimulate the immune system to induce t cell proliferation; To inhibit the proliferative activity of neoplastic cells; Use of ingenol mebutate to treat actinic kerat...
Dosage: GEL;TOPICAL